Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BIOMERIEUX. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
FilmArray continues to fuel the growth momentum
03 Nov 16
bioMerieux released Q3 FY16 trading results in line with street estimates. Total revenue increased by 9.1% at CER (vs Q3 15: +8.8%), fuelled by strong growth in the clinical applications segment (+9.8% vs Q3 15: +7.9%; c.81% of Q3 16 sales). Within the segment, the growth in the molecular biology business accelerated to +48.0% (vs Q3 15: +31.7%; c.16% of Q3 16 sales), led by strong demand for instruments in the FilmArray business line (+78.0% yoy). The strong performance continued in the microbiology business (+4.2% vs Q3 15: +3.0%; c.44% of Q3 16 sales), largely driven by the sales of BacT/ALERT blood culture and the VIRTUO product line (+12.0% yoy). However, growth in the immunoassays business slowed down (+4.4% vs Q3 15: +9.0%; c.21% of Q3 16 sales), due to increased competition in the routine testing franchise. The industrial applications segment witnessed an 8.7% increase in sales (vs Q3 15: +2.4%; c.19% of Q3 16 sales), driven by the sustained demand for VIDAS and VITEK product lines by the food sector and an increase in demand for flow cytometry solutions by the pharmaceutical sector. Geographically, the biggest beneficiary was the APAC region, wherein, sales were up 11.6% (vs Q3 15: +0.6%; c.18% of Q3 16 sales), on the back of robust growth in China, India and South Korea (all up by c.15%). Revenue growth also accelerated in the LatAm region (+14.2% vs Q3 15: +10.3%; c.7% of Q3 16 sales) as the demand in Brazil and Argentina gathered pace during the period. The positive momentum continued in North America (+18.4% vs Q3 15: +18.4%; c.35% of Q3 16 sales), benefiting from the strong uptake in installations of FilmArray systems across laboratories. However, growth in the EMEA region slumped to +1.0% (vs Q3 15: +4.9%; c.40% of Q3 16 sales), primarily due to a slowdown in the Middle East, France and in certain Southern European countries. The total reported revenue grew by 6.8% (vs Q3 15: +16.1%), reflecting a -1.3% currency effect and a -0.9% scope effect. Given the strong momentum registered in 9M, management expects the lfl revenue growth for FY16 to be above the higher end of the previous guidance of 6-8% range.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Panmure Morning Note 02-12-16
02 Dec 16
We expect CareTech to report FY results to September on 8th December. A positive trading update in October indicated that performance for the year was in line with market expectations therefore we are focusing on the outlook. We expect a confident statement since the end of 2016 showed positive trends across fee rates, expansion in places and occupancy. We believe CareTech is well positioned for further expansion, and remains at an attractive valuation. We retain our BUY and 380p price target.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.